Lexaria Bioscience Corp (LEXX)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$2.99

+0.17 (+6.03%)

Market Cap: $5.94M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

50%(10/20)

Avg Surprise

-10.71%

Upcoming Estimates

Period ending Aug 31, 2026

EPS Consensus$-3.79

Range$-3.79 - $-3.79

1 analysts

Revenue Consensus

$-130000

Range$-130000 - $-130000

1 analysts

Period ending Nov 30, 2026

EPS Consensus$N/A

Revenue Consensus

Range$0 - $0

0 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Nov 30, 2026Nov 26EST	-	N/A	-	-	-	-	-	-
Aug 31, 2026Aug 26EST	-	$-3.79	$-3.79 - $-3.79	-	-	1	-	-
May 31, 2026May 26 Reported Jul 13, 2026Reported Jul 13	$-0.08	$-0.06	$-0.06 - $-0.06	-33.33%	Miss	1	1 0 30d	+61.9%
Feb 28, 2026Feb 26 Reported Apr 13, 2026Reported Apr 13	$-0.06	$-0.07	$-0.07 - $-0.07	+14.29%	Beat	1	1 0 30d	+60.0%
Nov 30, 2025Nov 25 Reported Jan 13, 2026Reported Jan 13	$-0.07	$-0.13	$-0.13 - $-0.13	+46.15%	Beat	1	1 0 30d	+56.3%
Aug 31, 2025Aug 25 Reported Nov 26, 2025Reported Nov 26	$-0.14	$-0.15	$-0.18 - $-0.14	+9.68%	Beat	3	No revisions (30d)	+6.7%
May 31, 2025May 25 Reported Jul 14, 2025Reported Jul 14	$-0.21	$-0.14	$-0.14 - $-0.14	-50.00%	Miss	0	No revisions (30d)	-61.5%
Feb 28, 2025Feb 25 Reported Apr 14, 2025Reported Apr 14	$-0.15	$-0.16	$-0.16 - $-0.16	+6.25%	Beat	0	No revisions (30d)	-150.0%
Nov 30, 2024Nov 24 Reported Jan 10, 2025Reported Jan 10	$-0.16	$-0.12	$-0.12 - $-0.12	-33.33%	Miss	0	No revisions (30d)	-23.1%
Aug 31, 2024Aug 24 Reported Nov 26, 2024Reported Nov 26	$-0.15	$-0.11	$-0.11 - $-0.11	-36.36%	Miss	0	No revisions (30d)	-25.0%
May 31, 2024May 24 Reported Jul 12, 2024Reported Jul 12	$-0.13	$-0.09	$-0.13 - $-0.05	-44.44%	Miss	3	No revisions (30d)	+64.9%
Feb 29, 2024Feb 24 Reported Apr 9, 2024Reported Apr 9	$-0.06	$-0.10	$-0.10 - $-0.10	+40.00%	Beat	1	No revisions (30d)	+72.5%
Nov 30, 2023Nov 23 Reported Jan 12, 2024Reported Jan 12	$-0.13	$-0.11	$-0.11 - $-0.11	-18.18%	Miss	1	1 0 30d	+56.7%
Aug 31, 2023Aug 23 Reported Nov 21, 2023Reported Nov 21	$-0.12	$-0.13	$-0.17 - $-0.10	+7.69%	Beat	2	No revisions (30d)	+50.0%
May 31, 2023May 23 Reported Jul 14, 2023Reported Jul 14	$-0.37	$-0.25	-	-48.00%	Miss	-	-	+9.8%
Feb 28, 2023Feb 23 Reported Apr 14, 2023Reported Apr 14	$-0.22	$-0.22	$-0.22 - $-0.22	+0.86%	Beat	0	No revisions (30d)	+12.8%
Nov 30, 2022Nov 22 Reported Jan 17, 2023Reported Jan 17	$-0.30	$-0.30	$-0.30 - $-0.30	+0.00%	Beat	0	No revisions (30d)	+14.3%
Aug 31, 2022Aug 22 Reported Nov 25, 2022Reported Nov 25	$-0.24	$-0.21	$-0.21 - $-0.21	-14.29%	Miss	0	No revisions (30d)	-9.1%
May 31, 2022May 22 Reported Jul 14, 2022Reported Jul 14	$-0.41	$-0.28	$-0.28 - $-0.28	-46.43%	Miss	1	No revisions (30d)	+18.0%
Feb 28, 2022Feb 22 Reported Apr 11, 2022Reported Apr 11	$-0.25	$-0.21	$-0.21 - $-0.21	-19.05%	Miss	1	No revisions (30d)	-327.3%
Nov 30, 2021Nov 21 Reported Jan 14, 2022Reported Jan 14	$-0.35	$-0.35	$-0.35 - $-0.35	+0.00%	Beat	0	No revisions (30d)	-52.2%
Aug 31, 2021Aug 21 Reported Nov 29, 2021Reported Nov 29	$-0.22	$-0.23	$-0.23 - $-0.23	+4.35%	Beat	1	No revisions (30d)	-2100.0%
May 31, 2021May 21 Reported Jul 15, 2021Reported Jul 15	$-0.50	N/A	-	N/A	Beat	-	-	-2400.0%
Feb 28, 2021Feb 21 Reported Apr 14, 2021Reported Apr 14	$0.11	N/A	-	N/A	Beat	-	-	+1200.0%
Nov 30, 2020Nov 20 Reported Jan 14, 2021Reported Jan 14	$-0.23	N/A	-	N/A	Beat	-	-	-2200.0%
Aug 31, 2020Aug 20 Reported Oct 15, 2020Reported Oct 15	$-0.01	N/A	-	N/A	Beat	-	-	+0.0%
May 31, 2020May 20 Reported Jun 30, 2020Reported Jun 30	$-0.02	N/A	-	N/A	Beat	-	-	-100.0%
Feb 29, 2020Feb 20 Reported Apr 3, 2020Reported Apr 3	$-0.01	N/A	-	N/A	Beat	-	-	+0.0%
Nov 30, 2019Nov 19 Reported Jan 8, 2020Reported Jan 8	$-0.01	N/A	-	N/A	Beat	-	-	+0.0%
Aug 31, 2019Aug 19 Reported Nov 14, 2019Reported Nov 14	$-0.01	N/A	-	N/A	Beat	-	-	+50.0%
May 31, 2019May 19 Reported Jul 8, 2019Reported Jul 8	$-0.01	N/A	-	N/A	Beat	-	-	+80.0%
Feb 28, 2019Feb 19 Reported Apr 15, 2019Reported Apr 15	$-0.01	N/A	-	N/A	Beat	-	-	+50.0%
Nov 30, 2018Nov 18 Reported Jan 11, 2019Reported Jan 11	$-0.01	N/A	-	N/A	Beat	-	-	+0.0%
Aug 31, 2018Aug 18 Reported Nov 14, 2018Reported Nov 14	$-0.02	N/A	-	N/A	Beat	-	-	-100.0%
May 31, 2018May 18 Reported Jul 13, 2018Reported Jul 13	$-0.05	N/A	-	N/A	Beat	-	-	-400.0%
Feb 28, 2018Feb 18 Reported Apr 12, 2018Reported Apr 12	$-0.02	N/A	-	N/A	Beat	-	-	+91.7%
Nov 30, 2017Nov 17 Reported Jan 12, 2018Reported Jan 12	$-0.01	N/A	-	N/A	Beat	-	-	+95.6%
Aug 31, 2017Aug 17 Reported Nov 27, 2017Reported Nov 27	$-0.01	N/A	-	N/A	Beat	-	-	-
May 31, 2017May 17 Reported Jul 13, 2017Reported Jul 13	$-0.01	N/A	-	N/A	Beat	-	-	-
Feb 28, 2017Feb 17 Reported Apr 13, 2017Reported Apr 13	$-0.24	N/A	-	N/A	Beat	-	-	-
Nov 30, 2016Nov 16 Reported Jan 13, 2017Reported Jan 13	$-0.23	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-0.57	EV/EBITDA	N/A
Price/FCF	-0.66x	FCF Yield	-152.23%
Profitability
Profit Margin	0.00%	Operating Margin	-3863.00%
ROE	-162.80%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	10.60x	Quick Ratio	10.60x
Trading Statistics
Beta	0.60	Avg Volume	74.05K
52-Week High	$21.60	52-Week Low	$2.43

Technical Indicators Dashboard

Moving Averages

SMA 10$3.08

SMA 20$3.16

SMA 50$6.39

SMA 200$9.37

EMA 10$3.11

EMA 20$3.66

EMA 50$5.44

EMA 200$9.14

MACD

Line: -0.90Signal: -1.10Hist: 0.20

ADX

ADX: 22.7+DI: 15.5-DI: 20.5

Aroon & PSAR

Aroon UpN/A

Aroon Down96.0

PSAR$3.82

Bollinger Bands

Upper Band$3.56

Lower Band$2.75

%B Position2592%(Upper)

Band Width0.30

RSI (14-Day)

Neutral

37.1

Momentum Oscillators

Stoch %K24.6

Stoch %D28.4

Williams %R-61.9

ROC (10d)-3.2%

Momentum-0.10

CCI (20d)-94.4

MFI (14d)42.0

Volatility Measures

ATR (14d)$0.84(28.1%)

StdDev (20d)0.20

Hist Vol104.3%(High)

Volume Flow

VWAP$2.95

OBV-30.2M

AD Line26.7B

CMF (20d)-0.220

Volume Metrics

Avg Vol (20d)65.7K

Vol Ratio0.5x(Low)

VWMA (20d)$3.14

Pivot Points

R3$3.51

R2$3.21

R1$3.02

Pivot Point$2.72

S1$2.53

S2$2.23

S3$2.04

Advanced Oscillators

TSI-29.24

Ultimate Osc36.6

KST-409.48

Financial Data

Quarter	May 2026	Feb 2026	Nov 2025	Aug 2025	May 2025	Feb 2025	Nov 2024	Aug 2024	May 2024	Feb 2024	Nov 2023	Aug 2023
Total Revenue	$0	$20,000	$0	$174,000	$174,000	$174,000	$183,923	$84,000	$84,000	$145,000	$151,278	$-3,433
Cost of Revenue	$0	$26,568	$24,197	$21,398	$15,422	$17,809	$2,720	$16,370	$15,074	$15,931	$4,822	$56,173
Gross Profit	$0	$20,000	$-24,197	$174,000	$174,000	$174,000	$181,203	$84,000	$84,000	$145,000	$146,456	$-3,433

Operating Expenses	$1.99M	$1.47M	$1.57M	$2.86M	$3.92M	$2.93M	$2.87M	$2.29M	$1.83M	$813,005	$1.29M	$1.07M
R&D	$970,834	$475,388	$671,340	$1.88M	$2.72M	$1.69M	$1.95M	$967,206	$573,089	$245,779	$574,491	$500,406
SG&A	$1.02M	$996,515	$902,291	$980,477	$1.21M	$1.24M	$918,690	$1.32M	$1.25M	$567,226	$711,107	$566,673
Operating Income	$-1,993,804	$-1,451,903	$-1,573,631	$-2,688,597	$-3,750,421	$-2,751,012	$-2,690,707	$-2,203,064	$-1,742,919	$-668,005	$-1,139,142	$-1,070,512

Interest Income	$837	$1,769	$12	$2,816	$190	$0	$11	$6,993	$0	$0	$7,319	$0
Interest Expense	$0	$0	$22,081	$8,631	$40,185	$0	$15,921	$0	$41,393	$1	$45,896	$178,503
Income Before Tax	$-1,992,967	$-1,450,134	$-1,595,712	$-2,697,228	$-3,790,606	$-2,716,972	$-2,706,628	$-2,186,571	$-1,784,312	$-652,733	$-1,185,038	$-1,249,015
Income Tax Expense	$14	$2,598	$1,791	$0	$0	$3,760	$0	$0	$-2,623	$-3,195	$40,181	$-9,696

Net Income	$-1,991,202	$-1,449,979	$-1,595,007	$-2,695,838	$-3,789,092	$-2,713,212	$-2,703,699	$-2,184,790	$-1,781,693	$-649,539	$-1,179,323	$-1,239,319

EBITDA	$-1,973,759	$-1,431,033	$-1,578,846	$-2,675,830	$-3,759,651	$-2,714,695	$-2,673,433	$-2,194,331	$-1,769,238	$-636,801	$-1,156,260	$-1,178,087
EBIT	$-1,992,967	$-1,450,134	$-1,595,712	$-2,697,228	$-3,790,606	$-2,716,972	$-2,706,628	$-2,186,571	$-1,784,312	$-652,732	$-1,185,038	$-1,249,015

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about LEXX

News

Lexaria Bioscience Corp. (LEXX) Reports 566% Brain Uptake Gain With DHT-CBD in Animal Study

Lexaria Bioscience Corp. announced results from an animal study showing a 566% increase in brain tissue absorption for one of its DehydraTECH-CBD formulations compared to a reference. The company also filed three new...

TradingView•Oct 15, 2026 9:12 AM ET10/15/26•Bullish

Lexaria Bioscience Corp. (LEXX) Reports Animal Data on DehydraTECH CBD/GLP-1

Lexaria Bioscience Corp. (LEXX) announced animal study results for its DehydraTECH CBD and semaglutide formulations...

TradingView•Oct 15, 2026 9:12 AM ET10/15/26•Somewhat-Bullish

Lexaria Announces Results from Animal Study GLP-1-A26-1

Lexaria Bioscience Corp. announced results from its animal study GLP-1-A26-1, evaluating new formulation enhancements for DehydraTECH-CBD and DehydraTECH-semaglutide compositions. The study achieved superior absorption...

FinancialContent•Oct 15, 2026 9:12 AM ET10/15/26•Bullish

A CBD formula showed 566% more brain absorption in rats 8 hours after dosing.

Lexaria Bioscience (LEXX) announced results from its GLP-1-A26-1 animal study, showing that certain alternative DehydraTECH-CBD (DHT-CBD) formulations achieved significantly higher brain absorption compared to historical...

Stock Titan•Oct 15, 2026 9:12 AM ET10/15/26•Bullish

Lexaria Bioscience Corp. SEC Filing (Oct 14, 2026)

This article reports on Lexaria Bioscience Corp.'s SEC filing (Form S-3) which became effective on October 13, 2026, at 5:00 P.M. EDT. The filing is categorized as neutral in both impact and sentiment. The company...

Stock Titan•Oct 14, 2026 7:42 AM ET10/14/26•Neutral

LEXX Valuation and Fair Value

P/E: -0.6x
P/FCF: -0.7x
P/B: 1.0x

See GNG's fair value

LEXX Profitability: Margins, ROIC and FCF

Operating margin: -3863.0%
Net margin: 0.0%
ROE: -162.8%
FCF margin: -1388.8%
FCF yield: -152.2%

LEXX Competitors

Company	Ticker
Creative Medical Technology Holdings Inc	CELZ
Evogene	EVGN
WORK Medical Technology Group LTD Ordinary Shares	WOK
Can Fite Biopharma Ltd ADR	CANF
Healthcare Triangle Inc	HCTI
Imunon Inc	IMNN
Zhongchao Inc	ZCMD
Sonoma Pharmaceuticals Inc	SNOA

Sector: Healthcare

LEXX Bull Case vs Bear Case

Bear case

LEXX's quarterly revenue changed -88.5% year over year.

LEXX Earnings: Beat Rate and Next Report

Beat rate: 4 of 8 quarters (50.0%)
Average surprise: -9.6%
EPS estimate (fiscal period ending Aug 31, 2026): $-3.79

Frequently Asked Questions About LEXX

Does LEXX pay dividends?

Lexaria Bioscience Corp (LEXX) does not currently pay a regular dividend.

What is LEXX's market cap?

Lexaria Bioscience Corp (LEXX) has a market capitalization of $5.94M with a current stock price of $2.99.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In